-Andrew N Billin Researcher Activity Profile

Research Author Detailed Information 

Andrew N Billin Publication Rate By Year

Andrew N Billin has published 6 paper(s) in 2007, 3 paper(s) in 2008, for a total of 9 research publications in total.

Andrew N An Billin Author Information

LAST NAME: billin

FIRST NAME: Andrew N

INITIALS: an

AFFILIATION:

Papers

Andrew N Billin's Publication Record

1. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity. Year Published: 2007
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6149, USA.
2. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Year Published: 2007
Department of Veterinary and Biomedical Sciences , The Pennsylvania State University, 312 Life Sciences Building, University Park, Pennsylvania 16802, USA.
3. Peroxisome proliferator-activated receptor- /{delta} (PPAR /{delta}) ligands do not potentiate growth of human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and the Center of Molecular Toxicology and Carcinogenesis.
4. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and the Center of Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA 16802, USA.
5. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
6. Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor {beta}/{delta} (NR1C2) Antagonist. Year Published: 2008
GlaxoSmithKline, Research and Development, Research Triangle Park, North Carolina 27709. andrew.n.billin@GSK.com.
7. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Year Published: 2008
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
8. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
9. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Year Published: 2008
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.